Scoop has an Ethical Paywall
Novartis secure vital heart injection
Media release 3 August, 2007
Novartis secures vital heart injection
PHARMAC and pharmaceutical company Novartis have reached an agreement to secure supplies of the heart medicine metoprolol tartrate injection.
Today PHARMAC and Novartis finalised an agreement to supply a different brand of metoprolol injections. Supplies have been sourced from the United States and will be available in mid-August.
“We are delighted that Novartis has pulled out all the stops to source this product for New Zealand,” says PHARMAC’s medical director Dr Peter Moodie.
“This is a vitally important medicine for use in hospitals and the agreement will ensure that supply continues to be available.”
The Novartis product is not yet registered in New Zealand, and will be supplied under Section 29 of the Medicines Act, which requires doctors to inform patients they are using an unregistered medicine. Novartis has also committed to make every effort to obtain full registration.
Initially the agreement covers enough stock to supply New Zealand for the rest of the year, with provision for a continuation after that.
Dr Moodie says the agreement with Novartis is not for sole supply of metoprolol injection, and the door is open to AstraZeneca to continue supplying its product.
ENDS
Gordon Campbell: On The Hikoi Aftermath
Mana Mokopuna: Children And Young People Share Vital Insights On Healing From Family Violence And Sexual Violence In New Report
NZ Government: PM Marks One Year In Government
Helen Clark Foundation: Helen Clark Foundation Calls For Political Action To Reduce The Prevalence Of Junk Food And Improve Health Outcomes
Justice Committee: Further Decisions About Submissions Process For The Principles Of The Treaty Of Waitangi Bill
Infrastructure New Zealand: Single Agency Needed To Coordinate Climate Adaptation And Recovery
Free Speech Union: Fair Digital News Bargaining Bill Likely To Restrict Access To Information, Polling Shows Most Oppose
